X

Trial Profile

Phase 1/2 open-label study of lenalidomide in Chronic lymphocytic leukaemia

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 05 Oct 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenalidomide (Primary)
Indications Chronic lymphocytic leukaemia
Focus Adverse reactions

Most Recent Events

30 Sep 2021 According to a Starton Therapeutics media release, STAR-LLD SC is expected to enter clinical studies in Q1 2022. The company has completed a pre-IND meeting for STAR-LLD SC and all IND-enabling studies.
15 Jan 2021 New trial record
11 Jan 2021 According to a Starton Therapeutics media release, STAR-LLD SC material is expected to be shipped in Q2 2021 to initiate this study in the second half of 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com